Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
出版年份 2021 全文链接
标题
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
作者
关键词
-
出版物
Frontiers in Oncology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-02-13
DOI
10.3389/fonc.2020.585311
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- (2020) Chiaki Kurimoto et al. CANCER SCIENCE
- Mechanisms of checkpoint inhibition‐induced adverse events
- (2020) P. Urwyler et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry
- (2020) Rik J. Verheijden et al. CLINICAL CANCER RESEARCH
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
- (2020) Lihong Peng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
- (2020) Mitchell S von Itzstein et al. CLINICAL CHEMISTRY
- Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
- (2020) Seiichi Yano et al. EUROPEAN JOURNAL OF CANCER
- Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy
- (2020) Ryan T. Lewinson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
- (2020) Zia Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
- (2019) Jun Oyanagi et al. LUNG CANCER
- BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI PD-1 INDUCED THYROID DYSFUNCTION
- (2019) Rena M. Pollack et al. Endocrine Practice
- Development of immune checkpoint therapy for cancer
- (2019) Jill M. Fritz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors
- (2019) Alberto Pavan et al. ONCOLOGIST
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
- (2019) Shaheen Khan et al. SEMINARS IN CANCER BIOLOGY
- Management of immune related adverse events induced by immune checkpoint inhibition
- (2019) Andreas Teufel et al. CANCER LETTERS
- Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
- (2019) Sadal Refae et al. INVESTIGATIONAL NEW DRUGS
- C-reactive protein as an early marker of immune-related adverse events
- (2019) Amir-Reza Abolhassani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
- (2019) Omar Hasan Ali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
- (2019) Yeonghee Eun et al. Scientific Reports
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
- (2018) Sander Bins et al. BRITISH JOURNAL OF CANCER
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
- (2018) Vancheswaran Gopalakrishnan et al. CANCER CELL
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- The microbiome and autoimmunity: a paradigm from the gut–liver axis
- (2018) Bo Li et al. Cellular & Molecular Immunology
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
- (2018) Michael F. Gowen et al. Journal of Translational Medicine
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
- (2018) Taku Fujimura et al. Oncotarget
- Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
- (2018) Ronald Anderson et al. Frontiers in Oncology
- Association of anti-thyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
- (2018) Shiro Kimbara et al. CANCER SCIENCE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Immune dysregulation in cancer patients developing immune-related adverse events
- (2018) Shaheen Khan et al. BRITISH JOURNAL OF CANCER
- Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
- (2018) Maria Pia Pistillo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
- (2018) Omar Hasan Ali et al. EUROPEAN JOURNAL OF CANCER
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
- (2017) Clélia Coutzac et al. Journal of Crohns & Colitis
- Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
- (2017) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Eosinophils in Autoimmune Diseases
- (2017) Nicola L. Diny et al. Frontiers in Immunology
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
- (2016) V. Damuzzo et al. OncoImmunology
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy
- (2013) Georg Schett et al. NATURE MEDICINE
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- Increased Risk of Breast Cancer Associated with CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans
- (2012) Hai Lian et al. PLoS One
- Organ specific-autoantibodies: Their role as markers and predictors of disease
- (2008) Piercarlo Sarzi-Puttini et al. AUTOIMMUNITY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started